Who's who

3 Houston innovators to know this week

In honor of Labor Day, here are three Houston innovators who probably aren't taking the day off. Courtesy photos

It may be Labor Day, but some of the hardest working Houston innovators are probably still checking their email on their phones from the pool.

Here are this week's innovators to know around town.

Marie Myers, CFO of UiPath

Marie Myers is the CFO of UiPath. Courtesy of UiPath

Marie Myers is a self-proclaimed Houstonian, avid bike rider, and robotics nerd — for lack of a better word. She's had a 20-year career in tech — most roles based right here in town — and throughout her whole experience, robotics process automation has been the most exciting technology she's gotten to work with.

UiPath just opened an office in Houston earlier this year, and Myers serves the company as CFO. She first worked with UiPath on the client side of things, and the technology awed her. She says she jumped at the opportunity to join the organization.

"When I think about RPA, the world lights up for me," she says. "It's truly transformative."

Click here to read more about the company.

Marco Bo Hansen, chief customer officer at Sani nudge and his executive team

Marco Bo Hansen, right, the chief customer officer at Sani nudge. Courtesy of TMCx

The Sani nudge executives may not be from Houston, but we give the Denmark-based company a pass for all its success coming out of the Texas Medical Center's accelerator program earlier this year. Sani nudge is a medical device company that can better track and encourage hand sanitation. The company is headed to California after being selected for a prestigious program with the Mistletoe Foundation.

Dr. Marco Bo Hansen is the chief customer officer and says that he'll be vigilantly advocating that his Sani nudge colleagues and the Mistletoe researchers keep hospital patients and staff in mind as Sani nudge moves forward with its innovations.

"We have to make sure that our solutions always generate value to the end users and can easily be used by the clinicians, infection preventionists, and hospital managers," he says.

Click here to read more about the company.

Ashley Gilmore, CEO and co-founder of Tracts.co

When Ashley Gilmore was studying law — specifically for the purposes of going into oil and gas — it amazed him how non-digitized the industry was, especially the mineral buying process. Gilmore figured out a way how to use tech to make the process way easier — and cheaper.

Now, his company, Tracts, has a new land group that's growing at a revenue rate of 30 percent month to month. With more and more clients, Tracts engages more data. And, with more and more data, the product increases in value for his customers.

"For some of our clients, Tracts is now existential for their business," Gilmore says. "In other words, they wouldn't be able to operate on their current business model without Tracts."

Click here to read more about the company.

Trending News

Building Houston

 
 

BiVACOR has received fresh funding from its investors to further develop its artificial heart. Photo courtesy of BiVACOR

A Houston medical device company that is developing an artificial heart announced it has received investment funding to the tune of $18 million.

BiVACOR's investment round was led by Boston-based Cormorant Asset Management and Australia's OneVentures's Healthcare Fund III. According to the company, the funding will be deployed to continue research and development, hiring executives, and support the path to first in human trials.

“We are extremely grateful for the ongoing support from our core investors," says Thomas Vassiliades, who was named CEO of BiVACOR last year, in a news release. "This additional commitment further validates our technology and the need for improved options to treat end-stage biventricular heart failure.

“With this financing, we will be able to double the size of our organization and add key positions from the C-suite to research and development. We are well positioned to advance our preclinical activities and aim to conduct our First in Human early feasibility study planned for the end of the year,” he continues.

Billed as the first long-term treatment for patients with severe biventricular heart failure, the BiVACOR Total Artificial Heart is an implantable artificial heart that utilizes rotary blood pump technology. This technology includes magnetic levitation and is a "durable, reliable, and biocompatible heart replacement," per the company's release. It's about the size of a fist and can be used in a wide range of patients including some children and women and up to adult males.

“Under the leadership of its expert management team, the company has developed a credible strategy for growth as they march toward first in human studies,” says Jeannie Joughin, board chair and principal at One Ventures, in the release. “There is a huge gap in care for patients waiting for a heart transplant, and we are confident that BiVACOR will continue to execute its strategy to swiftly get the Total Artificial Heart into the patients who need it most.”

The company raised its $22 million series B round in early 2021, which was also led by Cormorant Asset Management and OneVentures. To date, BiVACOR has raised $60 million.

“BiVACOR continues to execute on its strategy, and there was no question that we would jump in to lead this funding,” says Bihua Chen, CEO and founder of Cormorant Asset Management. “We are impressed by BiVACOR’s world-class team and continued dedication to push the technology in the clinic. We’re excited to support their growth and vision to transform the treatment of biventricular heart failure with the world’s first fully MAGLEV total artificial heart.”

Founded in 2008, BiVACOR maintains offices in Cerritos, California, and Brisbane, Australia. The company is affiliated with Houston's Texas Heart Institute, where the world's first artificial heart was implanted. BiVACOR's headquarters is at the Texas Medical Center complex.

Trending News